Thrivent Financial for Lutherans
CHRS icon

Thrivent Financial for Lutherans’s Coherus Oncology CHRS Stock Holding History

Thrivent Financial for Lutherans’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-63,960
Closed -$273K – 2439
2023
Q2 		$273K Sell
63,960
-10
-0% -$59 ﹤0.01% 2347
2023
Q1 		$438K Sell
63,970
-2,248
-3% -$17.4K ﹤0.01% 2179
2022
Q4 		$524K Sell
66,218
-469
-0.7% -$3.61K ﹤0.01% 2095
2022
Q3 		$641K Buy
66,687
+3,553
+6% +$36K ﹤0.01% 1947
2022
Q2 		$457K Buy
63,134
+11,252
+22% +$97.8K ﹤0.01% 2130
2022
Q1 		$670K Buy
51,882
+17
+0% +$216 ﹤0.01% 2050
2021
Q4 		$828K Buy
51,865
+555
+1% +$9.71K ﹤0.01% 1966
2021
Q3 		$825K Sell
51,310
-3,186
-6% -$46.7K ﹤0.01% 1947
2021
Q2 		$754K Buy
54,496
+1,874
+4% +$26.5K ﹤0.01% 2002
2021
Q1 		$769K Buy
52,622
+142
+0.3% +$2.41K ﹤0.01% 2024
2020
Q4 		$912K Buy
52,480
+330
+0.6% +$5.88K ﹤0.01% 1813
2020
Q3 		$956K Buy
52,150
+1,104
+2% +$20.5K ﹤0.01% 1581
2020
Q2 		$912K Buy
+51,046
New +$864K ﹤0.01% 1562
2018
Q3 		– Sell
-58,137
Closed -$814K – 2011
2018
Q2 		$814K Buy
58,137
+314
+0.5% +$4.5K ﹤0.01% 1392
2018
Q1 		$639K Buy
57,823
+683
+1% +$7.47K ﹤0.01% 1498
2017
Q4 		$503K Hold
57,140
– – ﹤0.01% 1685
2017
Q3 		$762K Hold
57,140
– – ﹤0.01% 1325
2017
Q2 		$820K Hold
57,140
– – ﹤0.01% 1229
2017
Q1 		$1.21M Hold
57,140
– – 0.01% 1069
2016
Q4 		$1.61M Buy
+57,140
New +$1.6M 0.01% 945

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Thrivent Financial for Lutherans's CHRS Position: Q3 2023 in Review

Thrivent Financial for Lutherans sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 63,960 shares — an estimated $273K sold.

Thrivent Financial for Lutherans first reported a position in CHRS in Q4 2016 and held it in 20 quarters. The position peaked at $1.61M in Q4 2016. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • Thrivent Financial for Lutherans reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 63,960 Coherus Oncology shares in Q3 2023, an estimated $273K.
  • Thrivent Financial for Lutherans first reported a position in Coherus Oncology in Q4 2016 and held it in 20 quarters.
  • Thrivent Financial for Lutherans's Coherus Oncology position peaked at $1.61M in Q4 2016.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2023, filed 14 Nov 2023.